BCYC
Price
$6.82
Change
-$0.17 (-2.43%)
Updated
Dec 26 closing price
Capitalization
473.09M
66 days until earnings call
Intraday BUY SELL Signals
QURE
Price
$24.81
Change
-$0.38 (-1.51%)
Updated
Dec 26 closing price
Capitalization
1.55B
65 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

BCYC vs QURE

Header iconBCYC vs QURE Comparison
Open Charts BCYC vs QUREBanner chart's image
Bicycle Therapeutics
Price$6.82
Change-$0.17 (-2.43%)
Volume$158.06K
Capitalization473.09M
uniQure
Price$24.81
Change-$0.38 (-1.51%)
Volume$861.32K
Capitalization1.55B
BCYC vs QURE Comparison Chart in %
BCYC
Daily Signal:
Gain/Loss:
QURE
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
BCYC vs. QURE commentary
Dec 27, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BCYC is a Buy and QURE is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 27, 2025
Stock price -- (BCYC: $6.82 vs. QURE: $24.81)
Brand notoriety: BCYC and QURE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BCYC: 51% vs. QURE: 24%
Market capitalization -- BCYC: $473.09M vs. QURE: $1.55B
BCYC [@Biotechnology] is valued at $473.09M. QURE’s [@Biotechnology] market capitalization is $1.55B. The market cap for tickers in the [@Biotechnology] industry ranges from $117.45B to $0. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BCYC’s FA Score shows that 1 FA rating(s) are green whileQURE’s FA Score has 0 green FA rating(s).

  • BCYC’s FA Score: 1 green, 4 red.
  • QURE’s FA Score: 0 green, 5 red.
According to our system of comparison, BCYC is a better buy in the long-term than QURE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BCYC’s TA Score shows that 2 TA indicator(s) are bullish while QURE’s TA Score has 5 bullish TA indicator(s).

  • BCYC’s TA Score: 2 bullish, 6 bearish.
  • QURE’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, QURE is a better buy in the short-term than BCYC.

Price Growth

BCYC (@Biotechnology) experienced а -0.73% price change this week, while QURE (@Biotechnology) price change was +3.42% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.36%. For the same industry, the average monthly price growth was +0.27%, and the average quarterly price growth was +54.56%.

Reported Earning Dates

BCYC is expected to report earnings on Mar 03, 2026.

QURE is expected to report earnings on Mar 02, 2026.

Industries' Descriptions

@Biotechnology (+0.36% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
QURE($1.55B) has a higher market cap than BCYC($473M). QURE YTD gains are higher at: 40.487 vs. BCYC (-51.286). QURE has higher annual earnings (EBITDA): -146.3M vs. BCYC (-245.86M). QURE has more cash in the bank: 694M vs. BCYC (648M). BCYC has less debt than QURE: BCYC (5.74M) vs QURE (66.2M). BCYC has higher revenues than QURE: BCYC (28.3M) vs QURE (15.8M).
BCYCQUREBCYC / QURE
Capitalization473M1.55B31%
EBITDA-245.86M-146.3M168%
Gain YTD-51.28640.487-127%
P/E RatioN/AN/A-
Revenue28.3M15.8M179%
Total Cash648M694M93%
Total Debt5.74M66.2M9%
FUNDAMENTALS RATINGS
BCYC vs QURE: Fundamental Ratings
BCYC
QURE
OUTLOOK RATING
1..100
6313
VALUATION
overvalued / fair valued / undervalued
1..100
14
Undervalued
55
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9699
PRICE GROWTH RATING
1..100
6353
P/E GROWTH RATING
1..100
10090
SEASONALITY SCORE
1..100
5090

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BCYC's Valuation (14) in the null industry is somewhat better than the same rating for QURE (55) in the Biotechnology industry. This means that BCYC’s stock grew somewhat faster than QURE’s over the last 12 months.

BCYC's Profit vs Risk Rating (100) in the null industry is in the same range as QURE (100) in the Biotechnology industry. This means that BCYC’s stock grew similarly to QURE’s over the last 12 months.

BCYC's SMR Rating (96) in the null industry is in the same range as QURE (99) in the Biotechnology industry. This means that BCYC’s stock grew similarly to QURE’s over the last 12 months.

QURE's Price Growth Rating (53) in the Biotechnology industry is in the same range as BCYC (63) in the null industry. This means that QURE’s stock grew similarly to BCYC’s over the last 12 months.

QURE's P/E Growth Rating (90) in the Biotechnology industry is in the same range as BCYC (100) in the null industry. This means that QURE’s stock grew similarly to BCYC’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BCYCQURE
RSI
ODDS (%)
N/A
Bullish Trend 2 days ago
72%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
85%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bearish Trend 2 days ago
86%
Bullish Trend 2 days ago
80%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
73%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
75%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
87%
Advances
ODDS (%)
Bullish Trend 6 days ago
81%
Bullish Trend 6 days ago
76%
Declines
ODDS (%)
Bearish Trend 10 days ago
88%
Bearish Trend 17 days ago
86%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
81%
Aroon
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
BCYC
Daily Signal:
Gain/Loss:
QURE
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FEBIX15.850.04
+0.25%
First Eagle Global Income Builder I
JCMVX28.26N/A
N/A
JPMorgan Mid Cap Value C
RLESX26.13-0.06
-0.23%
Russell Inv US Small Cap Equity S
ADKSX33.37-0.09
-0.27%
Adirondack Small Cap
KMKNX74.39-0.79
-1.05%
Kinetics Market Opportunities No Load

BCYC and

Correlation & Price change

A.I.dvisor indicates that over the last year, BCYC has been loosely correlated with NRIX. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if BCYC jumps, then NRIX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BCYC
1D Price
Change %
BCYC100%
-2.43%
NRIX - BCYC
51%
Loosely correlated
-0.31%
NGNE - BCYC
50%
Loosely correlated
-0.30%
XNCR - BCYC
49%
Loosely correlated
-1.49%
SYRE - BCYC
49%
Loosely correlated
-0.33%
RGNX - BCYC
48%
Loosely correlated
-2.07%
More

QURE and

Correlation & Price change

A.I.dvisor indicates that over the last year, QURE has been loosely correlated with NEVPF. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if QURE jumps, then NEVPF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To QURE
1D Price
Change %
QURE100%
-1.51%
NEVPF - QURE
50%
Loosely correlated
N/A
AXON - QURE
42%
Loosely correlated
-1.24%
LXEO - QURE
42%
Loosely correlated
-2.94%
BCYC - QURE
38%
Loosely correlated
-2.43%
MLTX - QURE
37%
Loosely correlated
-0.29%
More